#incretin
3 articles tagged with #incretin
Tirzepatide vs Semaglutide — Dual vs Single Incretin Research
Tirzepatide and Semaglutide are the two most-studied incretin research peptides, but they target different receptor profiles. This head-to-head explains what GIP-receptor activation adds to a GLP-1 base, why Tirzepatide is GIP-biased, and how the two compounds compare in research applications.
Retatrutide — Triple GLP-1/GIP/Glucagon Agonist Research Review
Retatrutide is the first triple agonist of GLP-1, GIP, and glucagon receptors to enter major incretin research. This review walks through its mechanism — what each receptor arm contributes, why glucagon-receptor activation matters, and how the triple-receptor profile compares to dual-incretin compounds.
GLP-1 Incretin Research — Semaglutide, Tirzepatide, Retatrutide Compared
A receptor-pharmacology comparison of the three flagship incretin research peptides: Semaglutide (single GLP-1 agonist), Tirzepatide (dual GIP/GLP-1 co-agonist), and Retatrutide (triple GLP-1/GIP/glucagon agonist). What each receptor adds to the metabolic profile.